The S&P gained 0.1% alongside the Dow’s 0.46% jump, but lagging big tech drove the Nasdaq down 0.5%. Let’s get into it.

Fulcrum Therapeutics ($FULC) – Fulcrum shares turned into an inclined plane yesterday on positive trial data for their sickle cell disease drug. Shares soared 125.3%, and so did my respect for anyone who got my 5th simple-machines joke. The catchy-named drug, FTX-6058, showed results indicating positive effects in patients because of some sciencey words I didn’t understand. However I do understand that means $$$, which was confirmed during the rest of the release as revenue and EPS crushed estimates, making this pretty much the firm’s best day ever.

Fisker ($FSR) – For the first time in human history, an EV startup has investors believing they will make and deliver vehicles on time. Unthinkable, I know, but that was Morgan Stanley's sentiment yesterday on Fisker Inc, sending shares on a 25.6% tear. After going public in 2018, the stock was flat until July of 2020 when all you retail Kings made the chart look like a heart rate monitor. Now that Morgan Stanley has called the firm the “electric vehicle architect”, real excitement is growing. I guess Elon can go f*ck himself.

Kansas City Southern ($KSU) – In the hottest railroad story since Cornelius Vanderbilt was kicking around, Canadian companies are still trying to acquire Kansas City Southern, driving a 7.5% spike. Canadian Pacific Railway has come back with a $27bn offer, underbidding Canadian National Railway’s $28bn offer from a few weeks ago. The offer comes 10 days before KSU shareholders vote on the Canadian National offer, but all eyes are on the STB, the U.S. rail regulator, and their probability of approval. Wow, and I thought Canadians were supposed to be nice to each other.